{"filings":[{"id":697676,"accession_number":"0001104659-26-067002","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2026-05-27T21:00:57+00:00","items":["5.07"],"status":"ready","headline":"Elanco shareholders elect all director nominees, ratify EY, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected; highest support for Lawrence Kurzius (443M for).","Ratification of Ernst & Young as auditor for 2026: 480M for, 2.6M against.","Advisory vote on executive compensation approved: 383.5M for, 84.2M against.","Broker non-votes totaled 15.4M for director and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95098,"accession_number":"0001739104-26-000027","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q1 revenue +15% to $1.37B, raises FY2026 guidance across all metrics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1.37B (+15% reported, +10% organic constant currency); adjusted EPS $0.40 vs $0.37 prior year.","Full-year 2026 guidance raised: revenue $5,010-$5,085M, adj. EBITDA $975-$1,005M, adj. EPS $1.03-$1.09.","Q2 2026 guidance: revenue $1,300-$1,325M, adj. EBITDA $240-$260M, adj. EPS $0.25-$0.28.","Innovation revenue target raised to $1.2B; net leverage target improved to 3.0x-3.2x.","Credelio Quattro and Zenrelia post strong share gains; closed AHV International acquisition Apr 30."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1371000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107927,"accession_number":"0001739104-26-000008","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco reports Q4 revenue up 12% to $1.14B, net loss $276M; provides 2026 guidance in line with outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $1,144M (+12% reported, +9% organic CC); reported net loss $276M, adjusted EPS $0.13.","FY 2025 revenue $4,715M (+6% reported, +7% organic CC); reported net loss $232M, adjusted EPS $0.94.","2026 guidance: revenue $4,950-5,020M (4-6% organic CC growth), adjusted EBITDA $955-985M, adjusted EPS $1.00-1.06.","Raising 2026 innovation revenue target to $1.15B; delivered all 'Big 6' blockbuster products by end of 2025 with Befrena approval in Q4.","Recorded $155M restructuring charges in Q4 under Elanco Ascend; net leverage ratio improved to 3.6x."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":4715000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107926,"accession_number":"0001104659-26-002723","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elanco to present at J.P. Morgan Healthcare Conference; no new material information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation reiterates innovation, portfolio, productivity strategy, pipeline, financial outlook, and executive team insights from December Investor Day.","No new financial guidance or specific metrics provided; 2025 outlook remains as of November 5, 2025, and reaffirmed December 9, 2025.","Q4 2025 results expected to be announced in February 2026; no update in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124347,"accession_number":"0001104659-25-119486","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Elanco announces restructuring plan and three-year financial outlook; Befrena technical sections complete","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restructuring: ~300 jobs eliminated, ~300 shifted; ~$175M pretax charge (~$130M cash); closure of Kansas City implant facility, partial exit from Monheim Germany.","Three-year outlook: mid-single digit revenue growth, high-single digit adj. EBITDA growth, low double-digit adj. EPS growth starting 2026.","Befrena (IL-31 mAb) technical sections complete; administrative review underway; launch expected H1 2026.","Innovation revenue ~$1.1B in 2026; 5-6 blockbuster potential approvals expected 2026-2031.","Elanco Ascend: $200-250M adjusted EBITDA savings by 2030; ~$25M in 2026, ~$60M in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124346,"accession_number":"0001739104-25-000068","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q3 revenue $1.14B (+10% YoY); raises FY guidance, net leverage improves","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $1,137M (+10% reported, +9% organic CC); adjusted EPS $0.19 vs $0.13 YoY (+46%).","Adjusted EBITDA $198M (+21%); net leverage ratio improved to 3.7x from 4.3x at FY 2024 end.","Raises FY 2025 revenue guidance to $4,645-4,670M and adjusted EPS to $0.91-0.94 (from $0.85-0.91).","Pet Health revenue $533M (+10%), driven by Credelio Quattro ($100M net sales in <8 months) and Zenrelia.","Refinanced $2.1B Term Loan B, extending maturities through 2032 and reducing interest cost."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":3571000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124345,"accession_number":"0001104659-25-105246","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Elanco refinances $1.1B + €400M + $540M credit facilities; extends maturities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 3 to Credit Agreement signed Oct 31, 2025; refinances existing term loans.","New $1.1B USD term loan B due 2032, €400M euro term loan A due 2029, $540M farm credit due 2032.","Proceeds plus cash on hand used to repay all outstanding term loan B due 2027 and pay fees.","Lenders include JPMorgan Chase as administrative agent; Wilmington Trust as collateral agent.","Amendment also modifies certain covenants and terms of the credit agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141019,"accession_number":"0001739104-25-000052","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q2 rev +5% to $1.24B, raises FY2025 outlook; net leverage target improved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1,241M (+5% reported, +8% organic CC); adjusted EPS $0.26 vs $0.30 prior year.","FY2025 revenue guidance raised to $4,570-4,620M; adjusted EPS raised to $0.85-0.91.","Full-year innovation revenue target increased by $60M to $720-800M; Credelio Quattro and Experior drive growth.","Net leverage ratio improved to 4.0x at Q2 end; year-end target tightened to 3.8x-4.1x.","Robert VanHimbergen appointed EVP and CFO effective July 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":2434000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158796,"accession_number":"0001104659-25-063027","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Elanco extends receivables securitization facility to June 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term extended from August 3, 2026 to June 26, 2028 via First Amendment to Receivables Loan Agreement.","Amendments include updated Normal Concentration Percentages for Obligor categories and reporting date flexibility.","Covenant triggers revised: default ratio >2.00%, dilution ratio >2.75%, delinquency ratio >3.00%, DSO >70 days.","Elanco Animal Health Inc. reaffirms its role as performance guarantor; facility size undisclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158795,"accession_number":"0001104659-25-053305","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Elanco appoints Robert VanHimbergen as CFO effective July 7, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert VanHimbergen appointed EVP and CFO, effective July 7, 2025; Todd Young stays as advisor through Aug 31, 2025.","VanHimbergen previously SVP and CFO of Hillenbrand; prior 15 years at Johnson Controls and PwC.","Base salary $660k, target annual cash incentive 75% of base, annual long-term incentive target $2.645M.","Make-whole awards: cash bonus $890k (3-year clawback) and RSU $1.735M (3-year ratable vesting).","Company reaffirmed Q2 and FY 2025 guidance issued May 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158794,"accession_number":"0001104659-25-051136","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Elanco annual meeting results: directors elected, say-on-pay approved with 46.5% dissent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Kapila K. Anand and Paul Herendeen elected; Anand faced 156M votes against (34%).","Non-binding say-on-pay approved 244.5M to 212.5M (46.5% opposed).","Ratification of Ernst & Young as auditor passed with 470.1M votes in favor.","Advisory vote on executive compensation will be held annually until 2031."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158793,"accession_number":"0001739104-25-000040","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q1 beats; FY25 revenue raised to $4.51-4.58B; debt paydown accelerated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1,193M (-1% reported, +4% organic CC); adj EPS $0.37 vs $0.34 YoY, above guidance.","FY25 revenue guidance raised to $4,510-$4,580M on FX tailwind; adj EBITDA guidance unchanged at $830-$870M.","Accelerating debt paydown: gross debt reduction $450-500M expected; net leverage target improved to 3.9x-4.3x.","Pet Health revenue $635M (-1%); Credelio Quattro ~10% share; Zenrelia in 11,000 clinics (35% penetration).","Q2 guidance: revenue $1,175-$1,195M, adj EPS $0.17-$0.21; organic constant currency growth 4-6%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":1193000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177200,"accession_number":"0001104659-25-024432","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Elanco signs research agreement with WEDterinary for $4M gene therapy in cats; four directors departing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board to shrink to 11 directors; Bilbrey, Turner, Wallace won't stand for re-election; Doyle resigned.","Research agreement with WEDterinary (33%-owned by Doyle) for targeted gene therapy treating chronic kidney disease in cats.","Elanco US will pay up to $4 million to fund WED research, securing negotiation rights to resulting IP.","Doyle will continue advising Elanco on animal health innovation; Paul Herendeen to chair Finance Committee.","Agreement funded within R&D operating expenses; approved by Audit Committee under related person policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177199,"accession_number":"0001739104-25-000011","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q4 adjusted EPS $0.14, revenue $1.02B; FY 2025 guidance reflects FX headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $1,020M (-1% reported, +4% organic CC); adjusted EPS $0.14 (vs $0.08); adjusted EBITDA $177M (17.4% margin).","FY 2024 revenue $4,439M (flat reported, +3% organic CC); adjusted EPS $0.91 (vs $0.89); innovation revenue $461M (beat target).","FY 2025 guidance: revenue $4,445-4,510M; adjusted EPS $0.80-0.86; adjusted EBITDA $830-870M; mid-single-digit organic CC growth.","2025 innovation revenue target raised to $640-720M; net leverage 4.3x; expects FX headwind of $110M to revenue, $45M to EBITDA.","Q1 2025 guidance: revenue $1,155-1,180M; adjusted EPS $0.29-0.34; adjusted EBITDA $240-260M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":4439000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177198,"accession_number":"0001104659-25-002881","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elanco to present at J.P. Morgan Healthcare Conference on Jan 14, 2025; no new financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Jeff Simmons will present at the 43rd Annual J.P. Morgan Healthcare Conference.","Presentation filed as Exhibit 99.1 but contains no specific financial or strategic updates.","No material change in business or guidance disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193974,"accession_number":"0001104659-24-116942","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Elanco appoints Stacey Ma to board; board expands to 15 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ma appointed effective Nov 11, 2024; board increased from 14 to 15 directors.","Ma will serve on Innovation, Science and Technology Committee.","Ma is EVP of Pharmaceutical Development and Manufacturing at Gilead Sciences.","Her expertise in CMC and drug development supports Elanco's IPP strategy.","No related party transactions or arrangements in her appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193973,"accession_number":"0001739104-24-000036","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q3 revenue $1.03B, +1% organic; adj. EPS $0.13; 2024 guidance tightened","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net income $364M ($0.73 EPS) includes $640M pre-tax gain from July aqua divestiture; adjusted net income $66M ($0.13 EPS).","Full-year 2024 guidance tightened: revenue $4.42-$4.45B, adj. EBITDA $900-$930M, adj. EPS $0.89-$0.95 (midpoint unchanged).","U.S. FDA approved Zenrelia (JAK inhibitor for atopic dermatitis in dogs) and Credelio Quattro (broad-spectrum parasiticide).","Net leverage ratio 4.3x, down from 5.6x at June 30; aided by aqua divestiture proceeds and debt paydown.","Pet health revenue $486M (-2% organic); Farm animal $530M (+3% organic); cattle up 6% on Experior and Rumensin."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":3419000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193972,"accession_number":"0001104659-24-108914","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Elanco presents Zenrelia study showing similar serologic response; approved in Canada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study presented at ISCAID: 68 beagles given ilunocitinib at 1X or 3X label dose for 56 days; protective titer levels post-booster similar to control group.","No serious adverse events observed; supports safety of Zenrelia concurrent with core booster vaccinations including rabies.","Zenrelia (ilunocitinib) received regulatory approval in Canada; further details on Health Canada Drug Product Database."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210301,"accession_number":"0001104659-24-089000","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Elanco enters $350M incremental term loan facility due 2031 to repay existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New incremental term facility of $350M, matures on August 13, 2031.","Interest rate: 1.75% for Term Benchmark loans, 0.75% for ABR loans.","Proceeds used to repay certain existing term loans and for general corporate purposes.","Quarterly principal payments of $875,000 starting Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210300,"accession_number":"0001739104-24-000025","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q2 revenue $1.184B, adjusted EPS $0.30; raises full-year revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1.184B (+12% reported, +13% CC); pet health $579M (+12%), farm animal $594M (+13%).","Adjusted EPS $0.30 (+67% YoY); adjusted EBITDA $275M (23.2% margin) vs $222M (21.0%).","Full year organic CC revenue growth guidance raised to 3%-4% (from 2%-3%); adjusted EPS maintained at $0.88-$0.96.","Aqua divestiture closed July 9, ~$1.2B proceeds used to pay down debt; gross debt reduced to ~$4.5B; net leverage 5.6x.","Zenrelia FDA final 60-day review; approval expected late Sept. Bovaer commercial activities underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2389000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210299,"accession_number":"0001104659-24-078464","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Elanco completes sale of aqua business to Merck for ~$1.3B; debt reduction plan outlined","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale to Merck closed July 9 for ~$1.3B cash; net proceeds ~$1.05-1.1B for Q3 debt paydown.","Expected total debt paydown of ~$1.3-1.4B in 2024 from sale proceeds and base business cash flow.","Net debt to adjusted EBITDA target: mid-4x at 2024 year-end; improving to high-3x to low-4x in 2025.","Divestiture focuses Elanco on pet health and livestock; CFO cites three quarters of underlying revenue growth.","Additional financial outlook impact to be provided on Q2 2024 earnings call in August."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210298,"accession_number":"0001104659-24-077840","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Elanco extends revolver maturity to 2029, enhancing liquidity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended revolving credit facility maturity from Aug 1, 2025 to July 3, 2029.","Springing maturity if other long-term debt ≥$400M (91 days before that debt's maturity).","Amendment also modifies certain covenants and other terms in the credit agreement.","Existing revolving commitments terminated; new 2024 Extended Revolving Facility Commitments established."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228610,"accession_number":"0001104659-24-068253","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Elanco shareholders approve board declassification, majority voting, and special meeting rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declassified, majority vote standard adopted for uncontested director elections.","Shareholders granted right to amend bylaws and request special meetings under certain conditions.","Kathy Turner reappointed to 2025 class, Lawrence Kurzius to 2026 class to rebalance board terms.","All four director nominees elected with votes ranging from 337M to 373M for.","Auditor Ernst & Young ratified (454M for, 1.6M against); say-on-pay approved (409M for, 31M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228609,"accession_number":"0001739104-24-000016","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q1 revenue $1.205B; adjusted EPS $0.34; FY guidance updated with improved constant currency growth outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1.205B (-4% reported/CC); reported EPS $0.06, adjusted EPS $0.34; adjusted EBITDA $294M (-22%).","FY 2024 guidance: revenue $4.46-4.515B (2-3% CC growth), adjusted EBITDA $960M-$1B, adjusted EPS $0.88-$0.96.","Net leverage 6.1x; expects debt paydown $280-320M in 2024; aqua divestiture closing mid-2024 with proceeds $1.05-1.1B after tax.","Innovation revenue now expected $375-410M in 2024; three pipeline products (Bovaer, Zenrelia, Credelio Quattro) on track for H2 2024 approval.","Kexxtone sales paused due to EU CVMP review; expected ~$20M revenue and ~$18M adjusted EBITDA reduction vs Feb guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1205000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228608,"accession_number":"0001104659-24-041558","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Elanco appoints two directors, reaches cooperation agreement with Ancora","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Kathy Turner and Craig Wallace to the Board effective March 29, 2024; Board size increased from 12 to 14.","Turner and Wallace join the renamed Finance, Strategy and Oversight Committee.","Cooperation Agreement with Ancora includes standstill, voting commitments, and non-disparagement provisions.","Turner held senior roles at IDEXX and Abbott; Wallace has 30+ years at Fort Dodge, Trupanion, and Ceva."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247258,"accession_number":"0001739104-24-000004","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Elanco reports Q4 net loss $141M, full-year loss $1.23B; cuts 420 jobs in restructuring","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $1,035M (+5% YoY); reported net loss $141M ($0.29 EPS), adjusted EPS $0.08.","Full-year 2023 revenue $4,417M (flat YoY); net loss $1,231M; adjusted EBITDA $979M; adjusted EPS $0.89.","Full-year 2024 guidance: revenue $4,450-4,540M; adjusted EBITDA $960-1,010M; adjusted EPS $0.87-0.95.","Restructuring eliminates ~420 positions; charges $50-55M in 2024, annualized savings $30-35M.","Aqua business sale to Merck Animal Health for ~$1.3B expected mid-2024; proceeds to reduce debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":4417000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247257,"accession_number":"0001104659-24-010337","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Elanco sells aqua business to Merck Animal Health for $1.3B cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction valued at approx. 7.4x estimated 2023 revenue of $175M and adjusted EBITDA of $92M.","After-tax proceeds of $1.05B-$1.1B to be used to pay down Term Loan B debt, reducing interest expense ~$65M annually.","Pro forma net leverage ratio would have been ~5.0x for 2023, down from slight below midpoint of 5.5x-5.8x guidance.","Expected close around mid-2024, subject to regulatory approvals and customary conditions.","Divestiture includes ~280 employees, manufacturing sites in Canada and Vietnam, and R&D projects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247256,"accession_number":"0001104659-24-002283","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elanco files 8-K for J.P. Morgan conference presentation; no new financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company to present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024.","Exhibit 99.1 attached is a presentation slide; no specific financial figures or guidance changes provided.","No material new information beyond the conference participation and presentation title."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247255,"accession_number":"0001104659-24-000140","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elanco names Lawrence Kurzius next Chairman; proposes board declassification and majority voting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lawrence Kurzius to become Chairman after 2024 annual meeting; R. David Hoover remains on board.","Board to declassify, grant shareholders rights to amend bylaws and call special meetings.","Company to seek approval to change director elections from plurality to majority of votes cast.","Post-meeting: Michael Harrington to chair Corporate Governance, Kirk McDonald to chair Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264684,"accession_number":"0001739104-23-000021","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco reports Q3 2023 net loss of $1,096M on $1,042M goodwill impairment; raises adjusted EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,068M (+4% reported, +5% CC); Pet Health +6% CC, Farm Animal +4% CC.","Reported net loss $1,096M includes $1,042M goodwill impairment; adjusted EPS $0.18 (up 6% YoY).","Full-year 2023 guidance tightened: revenue $4,360-4,400M, adj. EPS $0.88-0.94 (prior $0.80-0.89).","Net leverage ratio 5.7x; Q4 guidance: revenue $978-1,018M, adj. EPS $0.07-0.13.","CEO: innovation pipeline Credelio Quattro, Bovaer, Zenrelia on track for H1 2024 US approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":3382000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264683,"accession_number":"0001104659-23-106600","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elanco to seek shareholder approval for board declassification and enhanced shareholder rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board to seek shareholder approval at 2024 annual meeting to declassify Board of Directors.","Proposal also includes allowing shareholders to amend Bylaws and call special meetings under certain conditions.","Follows elimination of supermajority vote requirements last year; reflects shareholder engagement since IPO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281923,"accession_number":"0001104659-23-088037","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Elanco Q2 revenue $1,057M, adj EPS $0.18; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,057M (-10% YoY); estimated $90-$110M ERP blackout impact shifted Q2 revenue to Q1.","Reported net loss $(97)M, adjusted net income $90M; adjusted EBITDA $222M (21.0% of revenue).","Full-year 2023 guidance raised: revenue $4,350-$4,410M, adjusted EPS $0.80-$0.89, adj. EBITDA $950-$1,010M.","New $300M accounts receivable securitization facility; proceeds to retire August 2023 bonds.","EPA completed review of Seresto, confirming continued registration; launched Canine Parvovirus Mab in U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":2314000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281922,"accession_number":"0001104659-23-080837","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"EPA completes Seresto review, confirms registration; Elanco implements stewardship program","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EPA completed multi-year review of Seresto collar, confirms continued registration; safety profile affirmed.","Elanco will implement stewardship program including enhanced AE reporting, separate dog/cat registrations, package insert updates.","Company expects no commercial disruption or material financial impact from stewardship program.","More than 41 million Seresto collars sold in U.S. since 2013; 2022 AE rate 0.116%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281921,"accession_number":"0001104659-23-079662","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Elanco delivers redemption notice for Senior Notes due August 2023; redemption set for August 7, 2023","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["On July 7, 2023, Elanco sent notice to redeem all outstanding Senior Notes due August 28, 2023.","Redemption date scheduled for August 7, 2023, three weeks before original maturity.","Redemption under Indenture dated August 28, 2018 with Deutsche Bank Trust Company Americas as Trustee.","No principal amount or interest rate disclosed; redemption follows standard notice procedure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300921,"accession_number":"0001104659-23-062858","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Elanco shareholders elect two directors despite majority against; stock plans approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors R. David Hoover and Deborah T. Kochevar elected with more against votes than for (125M vs 309M; 164M vs 269M) under plurality.","Say-on-pay approved with 351M votes for (81% of votes cast, excluding 13.2M broker non-votes).","Amended and Restated Employee Stock Purchase Plan approved (434M for, 0.6M against).","Amended and Restated 2018 Stock Plan approved (418M for, 17M against).","Directors Michael J. Harrington and Kirk P. McDonald elected with strong majorities (260M+ for each)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300920,"accession_number":"0001104659-23-057445","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q1 revenue $1.257B, adj EPS $0.45; raises low end of FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1,257M (+3% reported, +6% CC); includes estimated $90-110M benefit from ERP blackout.","Adjusted EPS $0.45 (+25% YoY); reported EPS $0.21 vs $0.10 prior year.","Full year 2023 guidance raised: revenue $4,310-4,400M, adj EPS $0.76-0.83.","Q2 guidance expects revenue $1,003-1,053M due to ERP blackout pull-forward; adj EPS $0.00-0.05.","Net leverage 5.4x; received USDA conditional approval for parvovirus antibody, submitted for IL-31 mAb."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1257000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320807,"accession_number":"0001104659-23-027183","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K/A","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco revises Q4/FY2022 results for immaterial errors; reports material weakness in internal controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2022 revenue revised down $3M to $985M; reported net loss increased to $55M; adjusted EBITDA $172M (down $2M).","Full year 2022 revenue revised down $7M to $4,411M; reported net loss $78M (up $4M); adjusted EBITDA $1,017M (down $6M).","Reported EPS unchanged at $(0.11) for Q4; full year reported EPS revised to $(0.16) from $(0.15); adjusted EPS unchanged.","Net leverage increased to 5.5x from 5.4x; no impact on 2023 guidance.","Material weakness in internal control over financial reporting related to income tax provisions identified in 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320810,"accession_number":"0001104659-23-023484","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q4 revenue $988M (-11% YoY), full year net loss $74M; guides FY2023 revenue $4.28-4.4B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $988M (-11% reported, -6% CER); Pet Health $423M (-14%), Farm Animal $552M (-9%).","Q4 reported net loss $54M ($0.11 loss per share); adjusted net income $95M, adjusted EPS $0.19.","Full year 2022 revenue $4,418M (-7% reported); reported net loss $74M; adjusted EBITDA $1,023M (23.2% margin).","FY2023 guidance: revenue $4,280-4,400M; adjusted EBITDA $920-1,000M; adjusted EPS $0.74-0.83.","Initiated JAK inhibitor submission to FDA; received FDA approval for Bexacat (feline diabetes); EPA approval for Advantage/K9 Advantix relaunch; Bovaer launch expected H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":4411000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320809,"accession_number":"0001104659-23-008591","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Elanco announces settlement of Tangible Equity Units; will issue ~17.2M shares on Feb 1, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Feb 1, 2023, holders receive 1.5625 shares per prepaid stock purchase contract; cash in lieu of fractional shares.","Elanco expects to issue ~17.2 million shares of common stock upon settlement of all outstanding contracts.","Final installment payment on amortizing notes will be made on Feb 1, 2023; Units will then cease to be outstanding.","Tangible Equity Units were originally issued in January 2020 with a 5.00% coupon rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320808,"accession_number":"0001104659-23-002071","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elanco discloses FDA submission for JAK inhibitor at JPM conference","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company notes Q4 2022 submission to FDA for its JAK inhibitor.","Presentation made at 41st Annual J.P. Morgan Healthcare Conference on Jan 10, 2023.","No financial results or guidance changes provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338947,"accession_number":"0001104659-22-115672","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q3 revenue $1,028M, net loss $49M; cuts FY 2022 guidance on FX and macro headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue down 9% reported (4% constant currency) to $1,028M; pet health fell 11%, farm animal down 7%.","Reported EPS $(0.10); adjusted EPS $0.20 (up 5% YoY); adjusted EBITDA $205M (19.9% margin, +120bps).","FY 2022 revenue guidance lowered to $4,385-4,430M (from $4,465-4,550M); adjusted EPS cut to $1.01-1.07 from $1.06-1.13.","Net leverage ratio 5.2x; $170M gross debt reduction in Q3; cash flow from ops $189M vs $89M YoY.","Pipeline: FDA submission for broad-spectrum parasiticide; SGLT-2 feline diabetes drug and parvovirus mAb expected approvals by early 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":3430000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356321,"accession_number":"0001104659-22-098400","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Scott Ferguson steps down from Elanco board to focus on other Sachem Head commitments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Ferguson, founder of Sachem Head Capital Management, resigned from Elanco's board effective Sept 7, 2022.","Ferguson's resignation is not due to any disagreement with Elanco on operations, policies, or practices.","Sachem Head, a large shareholder, will continue to engage with the board and management.","CEO Jeffrey Simmons highlighted strong execution and upcoming pet health submissions for innovation pipeline.","Chairman R. David Hoover thanked Ferguson for his contributions and partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356320,"accession_number":"0001104659-22-086903","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q2 revenue $1.177B down 8%; cuts full-year guidance on macro headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1,177M (-8% reported, -4% constant currency); Pet Health $612M (-11%), Farm Animal $553M (-2%).","Reported EPS $(0.04), adjusted EPS $0.36; adjusted EBITDA $300M (25.5% margin) vs $291M prior year.","Full-year revenue guidance cut to $4,465-$4,550M from $4,700-$4,755M; adjusted EPS now $1.06-$1.13 vs $1.15-$1.21.","Net leverage 5.3x; target ~5.0x by year-end; 60% gross margin and 31% adjusted EBITDA timeline extended.","In-licensed feline diabetes product under FDA review; Zorbium launched; pipeline on track for two blockbuster submissions."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2402000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374709,"accession_number":"0001104659-22-075806","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Elanco enters $175M incremental term facility, matures June 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$175M incremental term loan facility entered June 28, 2022; proceeds used to repay revolving facility borrowings.","Matures June 30, 2025; terms mirror existing term loan facility under the 2020 Credit Agreement.","Borrowers: Elanco Animal Health Inc. and Elanco US Inc.; Bank of America and others as term lenders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374708,"accession_number":"0001104659-22-062946","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Elanco shareholders approve ESPP, eliminate supermajority voting; director elected despite majority against","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved elimination of supermajority vote to remove directors, replaced with majority vote.","Approved Employee Stock Purchase Plan reserving 625,000 shares for employees.","Charter amendments to remove legacy parent provisions passed with 99.98% votes in favor.","Director Kapila Kapur Anand elected despite 50.1% against votes; other nominees received >86% support.","All six proposals passed at May 18, 2022 annual meeting; Ernst & Young ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374707,"accession_number":"0001104659-22-057216","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elanco Q1 revenue $1.225B, adj. EPS $0.36; FY22 guidance lowered on FX headwind of $140M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1,225M (-1% reported, +2% CER); reported net income $48M vs -$61M; adjusted EPS $0.36 vs $0.37.","FY22 revenue guidance cut to $4,700-4,755M from $4,745-4,800M due to incremental $45M FX headwind; adj. EPS guidance $1.15-1.21.","Strategic alliance with Royal DSM for exclusive U.S. rights to Bovaer methane-reducing feed additive; >$200M annual revenue potential.","Pet Health revenue $639M; Seresto grew 6% to $161M; Advantage declined 5% to $137M, with temporary U.S. stock-outs.","Completed $406M tender on 4.272% Senior Notes due 2023; new $250M term facility with Farm Credit; net leverage 5.6x."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":1225000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374706,"accession_number":"0001104659-22-047827","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Elanco enters $250M incremental term loan facility maturing April 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $250M incremental term facility under existing credit agreement; matures April 19, 2029.","Proceeds used to repay outstanding revolving facility borrowings.","Quarterly amortization of 0.25% of principal beginning Dec. 31, 2022.","Lender: Farm Credit Mid-America; Term Loan Administrative Agent: Goldman Sachs Bank USA.","Interest rate and repayment terms generally consistent with existing term loan facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374705,"accession_number":"0001104659-22-045250","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2022-04-13T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Elanco spins out microbiome platform into BiomEdit with $40M funding; tenders $406M of 2023 notes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elanco launches BiomEdit, a microbiome innovation company, with $40M Series A from Viking Global and Anterra Capital.","Elanco contributes IP and pipeline to BiomEdit; retains non-voting equity; combined Elanco/Ginkgo ownership ~40% fully diluted.","Tender offer: $406M (54.19%) of 4.272% notes due 2023 tendered; cap raised to $406M; early acceptance at $1,035 per $1,000.","BiomEdit to leverage Ginkgo's cell programming platform for probiotics, bioactives, and engineered microbial medicines.","Aaron Schacht named CEO of BiomEdit; enters consulting agreement with Elanco at $250/hour for advisory role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393171,"accession_number":"0001104659-22-039527","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elanco commences $250M tender offer for 4.272% 2023 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Commenced cash tender offer to purchase up to $250M principal of 4.272% Senior Notes due 2023.","Early tender consideration of $1,035 per $1,000 principal includes $30 early tender payment; deadline April 11, 2022.","Tender offer expires April 25, 2022; Citi acting as sole dealer manager.","Elanco may exercise early settlement election or increase tender cap if oversubscribed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393170,"accession_number":"0001104659-22-026319","cik":1739104,"company_name":"Elanco Animal Health Inc","ticker":"ELAN","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","5.03","9.01"],"status":"ready","headline":"Elanco FY21 rev $4,765M, adj EPS $1.05; Q4 adj EPS $0.21 (+75%); FY22 adj EPS guidance $1.18-1.24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2021 revenue $4,765M (+46% YoY); reported EPS -$0.97, adjusted EPS $1.05.","Q4 2021 revenue $1,113M (-2% YoY); adjusted EPS $0.21 (+75% YoY).","FY22 guidance: revenue $4,745-$4,800M, adjusted EPS $1.18-$1.24.","Restructuring: ~380 positions cut; synergy target raised to $345M by 2023.","Board eliminated supermajority voting and adopted proxy access for 3%+ shareholders owning ≥3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":4765000000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12071696740.176447,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-24T23:59:59+00:00|393170"}